Trial · NCT06272383

Croup Dosing Study

NCT06272383, Phase 3, Completed, University of Manitoba; results first posted 2025-09-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Croup Dosing Study. Trials, record NCT06272383. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06272383

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Croup Dosing Study
NCT number: NCT06272383
Status: Completed
Phases: Phase 3
Enrollment: 50 participants, actual
Lead sponsor: University of Manitoba
Conditions: Croup
Interventions: 0.15 mg/kg dexamethasone
First posted: 2024-02-22
Last updated: 2025-09-08
Results first posted: 2025-09-08

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Return Visits or Readmissions to the Hospital	Seven days following initial presentation to the ED with croup.	Return visits or readmissions to the hospital within 7 days following initial presentation to the ED with croup.
Secondary	Adverse Events	within 7 and 30 days of treatment.	Adverse events following treatment with either of the 2 doses of dexamethasone. AEs: Disseminated varicella, gastrointestinal bleeding, unspecified bleeding, pneumonia, sepsis, febrile convulsion, bacteria tracheitis, tachycardia/fast heartbeat, and restlessness.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Return Visits or Readmissions to the Hospital	Seven days following initial presentation to the ED with croup.		participants	NUMBER
SECONDARY	Adverse Events	within 7 and 30 days of treatment.		participants	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Return Visits or Readmissions to the Hospital	0.15mg/kg Dexamethasone	0	participants
Return Visits or Readmissions to the Hospital	Standard Practice of 0.6mg/kg Dexamethasone	2	participants
Adverse Events	0.15mg/kg Dexamethasone	0	participants
Adverse Events	Standard Practice of 0.6mg/kg Dexamethasone	0	participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	0.15mg/kg Dexamethasone	25
Overall Study	STARTED	Standard Practice of 0.6mg/kg Dexamethasone	25
Overall Study	COMPLETED	0.15mg/kg Dexamethasone	19
Overall Study	COMPLETED	Standard Practice of 0.6mg/kg Dexamethasone	21
Overall Study	NOT COMPLETED	0.15mg/kg Dexamethasone	6
Overall Study	NOT COMPLETED	Standard Practice of 0.6mg/kg Dexamethasone	4

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	0.15mg/kg Dexamethasone	19
Total, all-cause mortality	Standard Practice of 0.6mg/kg Dexamethasone	21
Total, other adverse events	0.15mg/kg Dexamethasone	19
Total, other adverse events	Standard Practice of 0.6mg/kg Dexamethasone	21
Total, serious adverse events	0.15mg/kg Dexamethasone	19
Total, serious adverse events	Standard Practice of 0.6mg/kg Dexamethasone	21

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
42249465	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
0.15mg/kg Dexamethasone vs Standard Practice of 0.6mg/kg Dexamethasone: Return Visits or Readmissions to the Hospital	Trial comparisons
0.15mg/kg Dexamethasone vs Standard Practice of 0.6mg/kg Dexamethasone: deaths from any cause	Trial comparisons
0.15mg/kg Dexamethasone vs Standard Practice of 0.6mg/kg Dexamethasone: Adverse Events	Trial comparisons
0.15mg/kg Dexamethasone vs Standard Practice of 0.6mg/kg Dexamethasone: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT06272383

GET https://conductscience.org/api/trials/v1/NCT06272383/registered

API reference For AI assistants